The US Food and Drug Administration has stated that the Johnson and Johnson single dose-vaccine is highly effective against severe Covid-19 as well as new variants of the virus.
The vaccine had a 72% efficacy in a US clinical trial with no reported deaths. A document containing the company’s trial has been prepared ahead of a meeting which will take place on Friday where it will be decided if the vaccine should be authorised.
The European Medicines Agency is set to make a decision on the vaccine’s approval by mid-March.
An analysis of the trials reported no specific safety concerns that would prevent the vaccine from being issued in emergency use authorisation.